Disc Medicine Options Volume Jumps, Signaling Bet on Q4 Bitopertin Trial Data

Options trading volume in Disc Medicine (Nasdaq: IRON) surged on September 30, with activity heavily skewed toward bullish calls, indicating that some market participants are positioning for a significant positive catalyst before the end of the year. The trading was highlighted by a large, specific bet on the timing of the company's anticipated Phase 3 trial results for its drug candidate, bitopertin.

A Closer Look at the Options Flow

The most significant activity centered on a massive trade that appeared to roll a bullish position forward and to a higher strike price. According to market data, a trader likely closed a position of approximately 5,000 October $75 call contracts and simultaneously opened a new position of a similar size in November $90 calls.

This type of trade, known as a diagonal spread, suggests the trader remains bullish on the stock but believes the anticipated positive news event will occur after the October 16 expiration but before the November 20 expiration. This timeline aligns with Wall Street expectations for Disc Medicine to release Phase 3 data for bitopertin in erythropoietic protoporphyria (EPP) during the fourth quarter of 2026.

Market Pricing in a Major Move

The broader options market reflects heightened anticipation for the biotech firm. Overall volume on the day reached 12,138 call contracts against just 1,173 puts, a lopsided ratio of more than 10-to-1. Key metrics underscore the market's expectation of a sharp price swing:

Ad

• Implied Volatility: Three-month implied volatility stood at 109.40%, signaling that options prices are baking in a binary, high-risk outcome consistent with pivotal clinical trial data.
• Volatility Skew: The skew, which measures the relative demand for puts versus calls, compressed, indicating aggressive buying of call options.

This activity comes as the stock has been under pressure, falling nearly 18% over the past month. The options positioning suggests some traders view the recent weakness as a buying opportunity ahead of the potential catalyst.

Technical and Fundamental Context

Disc Medicine's stock closed at $65.70 on September 30. While technical indicators show the stock is in a strong downtrend and near oversold levels, some chart patterns suggest a potential for trend exhaustion. The options activity provides a sharp contrast to the recent price action and a backdrop of recent insider sales, which were conducted under pre-arranged 10b5-1 trading plans.

Analysts at Cantor Fitzgerald have previously set a price target of $125 for IRON, implying significant upside from current levels. However, a negative outcome in the Phase 3 trial could lead to a substantial decline, a risk highlighted by the high implied volatility priced into the options market.